Key Drivers
- Gross Margin
- Negative Cash Flow
- Rich Valuation
AIAI Summary
TARS has moved from a pipeline bet to a commercial execution story as XDEMVY's strong uptake de-risks revenue, but with valuation already rich and cash burn still negative, the stock now depends on proving operating leverage and durable free cash flow—not just top-line growth.
Price Chart
Financial Metrics
Deep Analysis
Research tool. Not personalized advice.
Fundamental Analysis
Key Financial Insights:
- •Gross Margin
- •Negative Cash Flow
- •Rich Valuation
TARS has strong gross margins and liquidity, but persistent operating losses, negative free cash flow, and a still-rich valuation keep the outlook cautious.
Price Behavior
Key Price Behavior Insights:
- •Resistance holding
- •Support tested
- •Bounce faded
Over the last month, TARS has drifted lower and remains slightly bearish, with repeated failure near $64.8–$65.2, support around $59.6–$61.0, and only a partial rebound after the $59.65 dip.
Sharp drop to $59.65 followed by a rebound to $65.18
Sentiment & News
Key News Insights:
- •XDEMVY surge
- •Guidance held
- •TP-05 trial
Tarsus posted strong Q1 XDEMVY growth and a narrower loss, but unchanged full-year guidance, a new Lyme-prevention trial, and added consumer marketing led to mixed investor reaction.
Strong operating momentum and expanding commercial visibility support the long-term outlook, though steady guidance may limit near-term stock upside
Similar Companies in Healthcare
Other companies in the same sector with AI ratings